|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6 Pt 1
|
|
pubmed:dateCreated |
1999-6-24
|
|
pubmed:abstractText |
Mycophenolate mofetil (MMF), an ester of mycophenolic acid (MPA), was approved by the Food and Drug Administration in 1995 and is currently primarily indicated for the prophylaxis of rejection in renal transplant patients. The drug seems also to be of value in the treatment of psoriasis and rheumatic arthritis. Recently there have been 6 reported cases of successful treatment of blistering autoimmune diseases with MMF in combination with high dose prednisone therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0190-9622
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
957-60
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10365927-Aged,
pubmed-meshheading:10365927-Aged, 80 and over,
pubmed-meshheading:10365927-Autoimmune Diseases,
pubmed-meshheading:10365927-Drug Therapy, Combination,
pubmed-meshheading:10365927-Female,
pubmed-meshheading:10365927-Glucocorticoids,
pubmed-meshheading:10365927-Humans,
pubmed-meshheading:10365927-Immunosuppressive Agents,
pubmed-meshheading:10365927-Middle Aged,
pubmed-meshheading:10365927-Mycophenolic Acid,
pubmed-meshheading:10365927-Pemphigus,
pubmed-meshheading:10365927-Prednisone
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
|
|
pubmed:affiliation |
Department of Dermatology, University of Ulm, Germany.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
